Long-acting buprenorphine is a promising new treatment for opioid use disorder, but it usually requires a seven-day stabilization period before initiation. Here, researchers develop and evaluate a novel protocol for initiating long-acting injectable buprenorphine in a single day. The trial is small, but results are promising.

By successfully completing the test you will be awarded a certificate for 2 CME credit.

The FDA recently approved donanemab for early Alzheimer’s, offering new hope by slowing cognitive decline.